

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine



Migraines: Neurological and Psychiatric Perspectives

**Migraine and Its Connections
in Neurology and Psychiatry**
J.M. Gorman

ORIGINAL RESEARCH

**Topiramate in the Preventive Treatment
of Episodic Migraine: A Comorbid Analysis
From Pilot, Double-Blind, Placebo-Controlled Trials**
K.R. Edwards, D. Potter, S-C Wu, M. Kamin, and J. Hulihan

ORIGINAL RESEARCH

Restless Legs Syndrome and Migraines
W.B. Young, E.J. Piovesan, and K.M. Biglan

REVIEW

The Link Between Glutamate and Migraine
N.M. Ramadan

REVIEW

The Comorbidity of Migraine
K.R. Merikangas and N.C.P. Low

REVIEW

**Venlafaxine Treatment of
Obsessive-Compulsive Disorder:
Case Reports**
D. Marazziti

THE NEUROLOGY OF BEHAVIOR
**Magnetic Resonance Imaging
and Hallervorden-Spatz Syndrome**
M. Trimble

PRSR STD
US POSTAGE
PAID
HANOVER NH
PERMIT #192

CNS Spectrums
c/o PPS Medical Marketing Group
264 Passaic Ave.
Fairfield, NJ 07004-2595
CHANGE SERVICE REQUESTED

*****AUTOMATED MAIL PERMIT 871
4134581077 HNC063 P 1251
MICHAEL O FLANAGAN MD 5
507 TULANE PL NE FLY 11
ALBUQUERQUE NM 87106-1344 1286Z



CNS Spectrums is an
Index Medicus journal.



Time for wakefulness

PROVIGIL® (modafinil) TABLETS

BRIEF SUMMARY: Consult Package Insert for Complete Prescribing Information

INDICATIONS and USAGE: To improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.

CONTRAINDICATIONS: Known hypersensitivity to PROVIGIL.

PRECAUTIONS: General: Patients should be cautioned about operating an automobile or other hazardous machinery until they are reasonably certain that PROVIGIL therapy will not adversely affect their ability to engage in such activities.

Cardiovascular System: In clinical studies of PROVIGIL, signs and symptoms including chest pain, palpitations, dyspnea, and transient ischemic T-wave changes on ECG were observed in 3 subjects in association with mitral valve prolapse or left ventricular hypertrophy. It is recommended that PROVIGIL tablets not be used in patients with a history of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia or other clinically significant manifestations of mitral valve prolapse in association with CNS stimulant use. Patients with a recent history of MI or unstable angina should be treated with caution. Periodic monitoring of hypertensive patients taking PROVIGIL may be appropriate.

Central Nervous System: Caution should be exercised when PROVIGIL is given to patients with a history of psychosis.

Patients with Severe Renal Impairment: Treatment with PROVIGIL resulted in much higher exposure to its inactive metabolite, modafinil acid, but not PROVIGIL itself.

Patients with Severe Hepatic Impairment: PROVIGIL should be administered at a reduced dose because its clearance is decreased.

Patients Using Contraceptives: The effectiveness of steroidal contraceptives may be reduced when used with PROVIGIL and for 1 month after discontinuation. Alternative or concomitant methods of contraception are recommended during and for 1 month after treatment.

Information for Patients: Physicians are advised to discuss the following with patients taking PROVIGIL:

Pregnancy: Animal studies to assess the effects of PROVIGIL on reproduction and the developing fetus were not conducted so as to ensure a comprehensive evaluation of the potential of PROVIGIL to adversely affect fertility, or cause embryoletality or teratogenicity. Patients should notify their physician if they become pregnant or intend to become pregnant during therapy. They should be cautioned of the potential increased risk of pregnancy when using steroidal contraceptives (including depot or implantable contraceptives) with PROVIGIL and for 1 month after discontinuation. **Nursing:** Patients should notify their physician if they are breast feeding. **Concomitant Medication:** Patients should inform their physician if they are taking or plan to take any prescription or over-the-counter drugs, because of the potential for drug interactions. **Alcohol:** It is prudent to avoid alcohol while taking PROVIGIL. **Allergic Reactions:** Patients should notify their physician if they develop a rash, hives, or a related allergic phenomenon.

Drug Interactions: CNS Active Drugs: In a single-dose study, coadministration of PROVIGIL 200 mg with methylphenidate 40 mg delayed the absorption of PROVIGIL by approximately 1 hour. The coadministration of a single dose of clomipramine 50 mg with PROVIGIL 200 mg/day did not affect the pharmacokinetics of either drug. One incident of increased levels of clomipramine and its active metabolite desmethylclomipramine has been reported. In a single-dose study with PROVIGIL (50, 100 or 200 mg) and triazolam 0.25 mg, no clinically important alterations in the safety profile of either drug were noted. In the absence of interaction studies with monoamine oxidase (MAO) inhibitors, caution should be exercised.

Potential Interactions with Drugs That Inhibit, Induce, or Are Metabolized by Cytochrome P-450 Isoenzymes and Other Hepatic Enzymes: Chronic dosing of PROVIGIL 400 mg/day resulted in ~20% mean decrease in PROVIGIL plasma trough concentration suggesting that PROVIGIL may have caused induction of its metabolism. Coadministration of potent inducers of CYP3A4 (eg, carbamazepine, phenobarbital, rifampin) or inhibitors of CYP3A4 (eg, ketoconazole, itraconazole) could alter the levels of PROVIGIL. Caution needs to be exercised when PROVIGIL is coadministered with drugs that depend on hepatic enzymes for their clearance; some dosage adjustment may be required. Potentially relevant *in vivo* effects of PROVIGIL based on *in vitro* data are:

A slight induction of CYP1A2 and CYP2B6 in a concentration-dependent manner has been observed. A modest induction of CYP3A4 in a concentration-dependent manner may result in lower levels of CYP3A4 substrates (eg, cyclosporine, steroidal contraceptives, theophylline).

An apparent concentration-related suppression of expression of CYP2C9 activity may result in higher levels of CYP2C9 substrates (eg, warfarin, phenytoin).

A reversible inhibition of CYP2C19 may result in higher levels of CYP2C19 substrates (eg, diazepam, propranolol, phenytoin, S-mephenytoin).

In some patients deficient in CYP2D6, the amount of metabolism via CYP2C19 may be substantially larger. Co-therapy with PROVIGIL may increase levels of some tricyclic antidepressants (eg, clomipramine, desipramine).

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis: The highest dose studied in carcinogenesis studies represents 1.5 times (mouse) or 3 times (rat) the maximum recommended human daily dose of 200 mg on a mg/m² basis. There was no evidence of tumorigenesis associated with PROVIGIL administration in these studies, but because the mouse study used an inadequate high dose below that representative of a maximum tolerated dose, the carcinogenic potential in that species has not been fully evaluated. **Mutagenesis:** There was no evidence of mutagenic or clastogenic potential of PROVIGIL. **Impairment of Fertility:** When PROVIGIL was administered orally to male and female rats prior to and throughout mating and gestation at up to 100 mg/kg/day (4.8 times the maximum recommended daily dose of 200 mg on a mg/m² basis) no effects on fertility were seen. This study did not use sufficiently high doses or large enough sample size to adequately assess effects on fertility.

Pregnancy: Pregnancy Category C: Embryotoxicity was observed in the absence of maternal toxicity when rats received oral PROVIGIL throughout the period of organogenesis. At 200 mg/kg/day (10 times the maximum recommended daily human dose of 200 mg on a mg/m² basis) there was an increase in resorption, hydronephrosis, and skeletal variations. The no-effect dose for these effects was 100 mg/kg/day (5 times the maximum recommended daily human dose on a mg/m² basis). When rabbits received oral PROVIGIL throughout organogenesis at doses up to 100 mg/kg/day (10 times the maximum recommended daily human dose on a mg/m² basis), no embryotoxicity was seen. Neither of these studies, however, used optimal doses for the evaluation of embryotoxicity. Although a threshold dose for embryotoxicity has been identified, the full spectrum of potential toxic effects on the fetus has not been characterized. When rats were dosed throughout gestation and lactation at doses up to 200 mg/kg/day, no developmental toxicity was noted post-natally in the offspring. There are no adequate and well-controlled trials with PROVIGIL in pregnant women. PROVIGIL should be used during pregnancy only if the potential benefit outweighs the potential risk.

Labor and Delivery: The effect of PROVIGIL on labor and delivery in humans has not been systematically investigated. Seven normal births occurred in patients who had received PROVIGIL during pregnancy.

Nursing Mothers: It is not known whether PROVIGIL or its metabolite are excreted in human milk. Caution should be exercised when PROVIGIL is administered to a nursing woman.

PEDIATRIC USE: Safety and effectiveness in individuals below 16 years of age have not been established.

GERIATRIC USE: Safety and effectiveness in individuals above 65 years of age have not been established.

ADVERSE REACTIONS: PROVIGIL has been evaluated for safety in over 2200 subjects, of whom more than 900 subjects with narcolepsy or narcolepsy/hypersomnia were given at least 1 dose of PROVIGIL. In controlled clinical trials, PROVIGIL was well tolerated, and most adverse experiences were mild to moderate. The most commonly observed adverse events (≥5%) associated with the use of PROVIGIL more frequently than placebo-treated patients in controlled US and foreign studies were headache, infection, nausea, nervousness, anxiety, and insomnia. In US controlled trials, 5% of the 369 patients who received PROVIGIL discontinued due to an adverse experience. The most frequent (≥1%) reasons for discontinuation that occurred at a higher rate for PROVIGIL than placebo patients were headache (1%), nausea (1%), depression (1%) and nervousness (1%). The incidence of adverse experiences that occurred in narcolepsy patients at a rate of ≥1% and were more frequent in patients treated with PROVIGIL than in placebo patients in US controlled trials are listed below. Consult full prescribing information on adverse events.

Body as a whole: Headache, chest pain, neck pain, chills, rigid neck, fever/chills

Digestive: Nausea, diarrhea, dry mouth, anorexia, abnormal liver function, vomiting, mouth ulcer, gingivitis, thirst

Respiratory system: Rhinitis, pharyngitis, lung disorder, dyspnea, asthma, epistaxis

Nervous system: Nervousness, dizziness, depression, anxiety, cataplexy, insomnia, paresthesia, dyskinesia, hypertonia, confusion, amnesia, emotional lability, ataxia, tremor

Cardiovascular: Hypotension, hypertension, vasodilation, arrhythmia, syncope

Hemic/Lymphatic: Eosinophilia

Special senses: Amblyopia, abnormal vision

Metabolic/Nutritional: Hyperglycemia, albuminuria

Musculo-skeletal: Joint disorder

Skin/Appendages: Herpes simplex, dry skin

Urogenital: Abnormal urine, urinary retention, abnormal ejaculation

¹Incidence ≥5%; ²Elevated liver enzymes; ³Oro-facial dyskinesias; ⁴Incidence adjusted for gender.

Dose Dependency: In US trials, the only adverse experience more frequent (≥5% difference) with PROVIGIL 400 mg/day than PROVIGIL 200 mg/day and placebo was headache.

Vital Signs Changes: There were no consistent effects or patterns of change in vital signs for patients treated with PROVIGIL in the US trials.

Weight Changes: There were no clinically significant differences in body weight change in patients treated with PROVIGIL compared to placebo.

Laboratory Changes: Mean plasma levels of gamma-glutamyl transferase (GGT) were higher following administration of PROVIGIL but not placebo. Few subjects (1%) had GGT elevations outside the normal range. Shift to higher, but not clinically significantly abnormal, GGT values appeared to increase with time on PROVIGIL. No differences were apparent in alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total protein, albumin, or total bilirubin. There were more elevated eosinophil counts with PROVIGIL than placebo in US studies; the differences were not clinically significant.

ECG Changes: No treatment-emergent pattern of ECG abnormalities was found in US studies following administration of PROVIGIL.

Postmarketing Reports

In addition to the adverse events observed during clinical trials, the following adverse events have been identified during post-approval use of PROVIGIL in clinical practice. Because these adverse events are reported voluntarily from a population of uncertain size, reliable estimates of their frequency cannot be made.

Hematologic: Agranulocytosis

Central Nervous System: Symptoms of psychosis, symptoms of mania

DRUG ABUSE and DEPENDENCE: Abuse Potential and Dependence: In addition to wakefulness-promoting effect and increased locomotor activity in animals, in humans, PROVIGIL produces psychoactive and euphoric effects, alterations in mood, perception, thinking, and feelings typical of other CNS stimulants. *In vitro*, PROVIGIL binds to the dopamine reuptake site and causes an increase in extracellular dopamine but no increase in dopamine release. PROVIGIL is reinforcing, as evidenced by its self-administration in monkeys previously trained to self-administer cocaine. In some studies PROVIGIL was also partially discriminated as stimulant-like. Physicians should follow patients closely, especially those with a history of drug and/or stimulant (eg, methylphenidate, amphetamine, or cocaine) abuse. Patients should be observed for signs of misuse or abuse (eg, incrementation of doses or drug-seeking behavior). In individuals experienced with drugs of abuse, PROVIGIL produced psychoactive and euphoric effects and feelings consistent with other scheduled CNS stimulants (methylphenidate). Patients should be observed for signs of misuse or abuse.

Withdrawal: Following 9 weeks of PROVIGIL use in 1 US trial, no specific symptoms of withdrawal were observed during 14 days of observation, although sleepiness returned in narcoleptic patients.

OVERDOSAGE: Human Experience: A total of 151 doses of ≥1000 mg/day (5 times the maximum recommended daily dose) have been recorded for 32 individuals. Doses of 4500 mg and 4000 mg were taken intentionally by 2 patients participating in foreign depression studies. In both cases, adverse experiences observed were limited, expected, and not life-threatening, and patients recovered fully by the following day. The adverse experiences included excitation or agitation, insomnia, and slight or moderate elevations in hemodynamic parameters. In neither of these cases nor in others with doses ≥1000 mg/day, including experience with up to 21 consecutive days of dosing at 1200 mg/day, were any unexpected effects or specific organ toxicities observed. Other observed high-dose effects in clinical studies have included anxiety, irritability, aggressiveness, confusion, nervousness, tremor, palpitations, sleep disturbances, nausea, diarrhea, and decreased prothrombin time. **Overdose Management:** No specific antidote to the toxic effects of PROVIGIL overdose has been identified. Overdoses should be managed with primarily supportive care, including cardiovascular monitoring. Emesis or gastric lavage should be considered. There are no data suggesting that dialysis or urinary acidification or alkalinization enhance drug elimination. The physician should consider contacting a poison-control center on the treatment of any overdose.

Manufactured for: Cephalon, Inc., West Chester, PA 19380

For more information about PROVIGIL, please call Cephalon Professional Services at 1-800-896-5855 or visit our Website at www.PROVIGIL.com.

 © 2003 Cephalon, Inc. PRO338 Feb 2003 All rights reserved. Printed in USA.

PROVIGIL®
(MODAFINIL) Tablets

Author Guidelines

Introduction

CNS Spectrums is an *Index Medicus* journal that publishes original scientific literature and reviews on a wide variety of neuroscientific topics of interest to the clinician. *CNS Spectrums* will publish 12 issues in 2003. As the immense prevalence of comorbid diseases among patients seen by psychiatrists and neurologists increases, these physicians will jointly diagnose and treat the neuropsychiatrically ill. Our mission is to provide these physicians with an editorial package that will enhance and increase their understanding of neuropsychiatry; therefore, manuscripts that address crossover issues germane to neurology and psychiatry will be given immediate priority.

Scope of Manuscripts

CNS Spectrums will consider the following types of articles for publication:

Original Research: Original Research presents methodologically sound original data.

Reviews: Reviews are **comprehensive** articles that summarize and synthesize the literature on various topics in a scholarly and clinically relevant fashion. Suitable topics include mood disorders, schizophrenia and related disorders, personality disorders, substance-use disorders, anxiety disorders, neuroscience, psychosocial aspects of psychiatry, child psychiatry, geriatric psychiatry, and other topics of interest to clinicians. Original flowcharts designed to aid the clinician in diagnosis and treatment will be considered for publication in reviews and are encouraged.

Case Reports: Single or multiple case reports will be considered for publication.

Letters to the Editor: Letters will be considered for publication.

Manuscript Submission

General information: Two copies of the manuscript with a letter on the author's letterhead should be submitted to Jack M. Gorman, Editor (or, in Europe, to Joseph Zohar, International Editor), c/o MBL Communications, 333 Hudson Street, 7th Floor, New York, NY 10013; (F) 212.328.0600. Authors are also required to submit their manuscripts on computer disk in Microsoft Word format. Disks should be labeled with the word processing program, title of paper, and lead author's name. Accepted manuscripts and letters will be edited for clarity and style.

Letters of permission to reproduce previously published material: All material reproduced from previously published copyrighted material must be accompanied by a letter of permission from the copyright holder. All such material should include a full credit line (eg, in the figure or table legend) acknowledging the original source. Any citation of unpublished material or personal communication should also be accompanied by a letter of permission for anyone who is not an author of the paper.

Peer review: Authors must provide five names of particularly qualified potential reviewers with no conflict of interest in reviewing the work. Contact information, including complete address, phone, fax numbers, E-mail address, and affiliations, should be included. The corresponding author will be notified by the editors when a decision regarding acceptance has been made. Peer review is anonymous.

Manuscript Preparation

Length: Reviews and Original Research should not exceed 5,000 words (excluding References). Letters should not exceed 1,500 words. Single Case Reports should not exceed 3,750 words and may be submitted with a photograph, if applicable. Diagnostic/treatment algorithms (see Reviews) should contain an extensive introduction, flowchart or series of graphs that fill 8–12 journal pages, and a concise summary.

Please note: If your article is **Original Research**, it should be formatted as: Abstract (100–200 words); Introduction, Materials/Methods; Results; Discussion; Conclusion; References (numbered and comprehensive list).

Spacing: One space should be left after commas and periods. Manuscripts should be double-spaced.

Abstract: Authors must provide a brief abstract.

Focus/Talking Points: Please provide three to six points that dictate the main focus of the manuscript, similar to teaching objectives, in bulleted format. These take-home points should clearly illustrate what you are trying to convey in the article.

References: American Medical Association style. See the following examples:

1. Jones J. Necrotizing *Candida* esophagitis. *JAMA*. 1980;244:2190-2191.
2. Stryer L. *Biochemistry*. 2nd ed. San Francisco, Calif: WH Freeman Co; 1980:559-596.

Continuing Medical Education: Authors must submit four multiple-choice questions (two Type A and two Type K), with answers.

Copyright: Materials are accepted for exclusive publication in *CNS Spectrums* and become the property of *CNS Spectrums*. Permission to reproduce material must be obtained from the publisher.

Disclosure of Commercial Interests

Authors must include a statement about all forms of support, including grant and drug company support. Such information may, at the editor's discretion, be shared with reviewers. If the article is accepted for publication, the editors will consult with the authors as to whether this information should be included in the published paper.

Submission Checklist

- Original manuscript plus one copy, with cover letter on author's letterhead
- Copies of permission letters to reproduce previously published and unpublished material
- A brief abstract of the article
- Four CME multiple-choice questions with answers
- Three to six focus points
- Disk labeled with the word processing program, title of paper, and lead author's name
- Names and addresses of two potential reviewers





Time for wakefulness

A unique wake-promoting agent

PROVIGIL promotes daytime wakefulness, improving patients' ability to participate in daily activities—with no effect on nighttime sleep.¹⁻³

Long-term safety

The long-term safety profile of PROVIGIL has been demonstrated for up to 136 weeks.⁴

PROVIGIL was generally well tolerated. Most frequently reported adverse events in clinical trials were headache, nausea, nervousness, anxiety, infection, and insomnia. Most adverse events were mild to moderate. PROVIGIL may interact with drugs that inhibit, induce, or are metabolized by cytochrome P450 isoenzymes.

Dosing

Recommended dose for PROVIGIL is 200 mg taken orally once daily in the morning. Both PROVIGIL doses, 200 mg and 400 mg QD, were effective.

PROVIGIL is indicated to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.

References: 1. PROVIGIL full prescribing information. 2. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. *Ann Neurol.* 1998;43:88-97. 3. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. *Neurology.* 2000;54:1166-1175. 4. Data on file, Cephalon, Inc.

PROVIGIL[®]
(MODAFINIL)[®]
Tablets

Wake up to life.[™]

Please see brief summary of prescribing information on adjacent page.
For more information, call 1-800-896-5855 or visit our Website at www.PROVIGIL.com.

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

EDITOR

Jack M. Gorman, MD
Mount Sinai School of Medicine
New York, NY

ASSOCIATE AND FOUNDING EDITOR

Eric Hollander, MD
Mount Sinai School of Medicine
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Stellenbosch
Tygerberg, South Africa

FAR EAST

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING WRITERS

Keith R. Edwards, MD
Donatella Marazziti, MD
Kathleen Ries Merikangas, PhD
Nabih M. Ramadan, MD
Michael Trimble, MD, FRCP, FRPsych
William B. Young, MD

BOARD OF ADVISORS

NEUROLOGISTS

Mitchell F. Brin, MD
University of California, Irvine
Irvine, CA

Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA

Jerome Engel, Jr., MD, PhD
University of California, Los Angeles
Los Angeles, CA

Mark S. George, MD
Medical University of South Carolina
Charleston, SC

C. Warren Olanow, MD, FRCP
Mount Sinai School of Medicine
New York, NY

Steven George Pavlakis, MD
Maimonides Medical Center
Brooklyn, NY

Michael Trimble, MD, FRCP, FRPsych
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Margaret Altemus, MD
Cornell University Medical College
New York, NY

Dennis S. Charney, MD
National Institute of Mental Health
Bethesda, MD

Dwight L. Evans, MD
University of Pennsylvania
Philadelphia, PA

Siegfried Kasper, MD
University of Vienna
Vienna, Austria

Martin B. Keller, MD
Brown Medical School
Providence, RI

Lorrin M. Koran, MD
Stanford University School of Medicine
Stanford, CA

Yves Lecrubier, MD
Hôpital de la Salpêtrière
Paris, France

Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN

Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom

Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA

Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico

Katharine Phillips, MD
Brown Medical School
Providence, RI

Harold A. Pincus, MD
Western Psychiatric Institute & Clinic
RAND-University of Pittsburgh Health
Institute, Pittsburgh, PA

Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA

Alan F. Schatzberg, MD
Stanford University School of Medicine
Stanford, CA

Stephen M. Stahl, MD, PhD
University of California, San Diego
La Jolla, California

Norman Sussman, MD, DFAPA
New York University Medical School
New York, NY

Karen Dineen Wagner, MD, PhD
The University of Texas Medical Branch
Galveston, Texas

Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands

Stuart C. Yudofsky, MD
Baylor College of Medicine
Houston, TX

MBL COMMUNICATIONS Corporate Staff

CEO & PUBLISHER

Darren L. Brodeur

ASSOCIATE PUBLISHER

Elizabeth Katz

MANAGING EDITOR

Christopher Naccari

SENIOR EDITOR

Deborah Hughes

DEPUTY SENIOR EDITOR

José R. Ralat

ACQUISITIONS EDITOR

Lisa Arrington

ASSISTANT ACQUISITIONS EDITOR

Eileen S. Seligman

EDITORIAL ASSISTANT

Shelley Wong

PRODUCTION MANAGER

Lila Moses

GRAPHIC DESIGNER

Anthony J. Korsak

DESIGNER, MULTIMEDIA

Michael Mosley

CONTROLLER

John Spano

NATIONAL ACCOUNT MANAGER

Kelly J. Staley

CME PROJECTS DIRECTOR

Chris Van Denburg

OFFICE MANAGER

Claudette Crawford

OFFICE ASSISTANT

Manuel Pavón

INFORMATION TECHNOLOGY

Adam Bolt

CORPORATION COUNSEL

Kevin F. Saer, Esq.
Davis, Wright, and Tremaine

OF COUNSEL

Lawrence Ross, Esq.
Bressler, Amery, and Ross

EDITORIAL MISSION

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journal's goal is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.

ABILIFY™ (aripiprazole) Tablets

Rx only

Brief Summary of Prescribing Information. For complete prescribing information please consult official package circular.

INDICATIONS AND USAGE

ABILIFY (aripiprazole) is indicated for the treatment of schizophrenia. The efficacy of ABILIFY in the treatment of schizophrenia was established in short-term (4- and 6-week) controlled trials of schizophrenic inpatients (see **CLINICAL PHARMACOLOGY: Clinical Studies**). The long-term efficacy of aripiprazole in the treatment of schizophrenia has not been established. The physician who elects to use ABILIFY for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

CONTRAINDICATIONS

ABILIFY is contraindicated in patients with a known hypersensitivity to the product.

WARNINGS

Neuroleptic Malignant Syndrome (NMS): A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including aripiprazole. Two possible cases of NMS occurred during aripiprazole treatment in the premarketing worldwide clinical database. Clinical manifestations of NMS are hyperreflexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude causes where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. **Tardive Dyskinesia:** A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and, thereby, may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, ABILIFY should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on ABILIFY, drug discontinuation should be considered. However, some patients may require treatment with ABILIFY despite the presence of the syndrome.

PRECAUTIONS

General: Orthostatic Hypotension: Aripiprazole may be associated with orthostatic hypotension, perhaps due to its α_1 -adrenergic receptor antagonism. The incidence of orthostatic hypotension associated events from five short-term, placebo-controlled trials in schizophrenia ($n=926$) on ABILIFY (aripiprazole) included: orthostatic hypotension (placebo 1%, aripiprazole 1.9%), orthostatic lightheadedness (placebo 1%, aripiprazole 0.9%), and syncope (placebo 1%, aripiprazole 0.6%). The incidence of a significant orthostatic change in blood pressure (defined as a decrease of at least 30 mmHg in systolic blood pressure when changing from a supine to standing position) for aripiprazole was not statistically different from placebo (14% among aripiprazole-treated patients and 12% among placebo-treated patients). Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). **Seizure:** Seizures occurred in 0.1% (1/926) of aripiprazole-treated patients in short-term, placebo-controlled trials. As with other antipsychotic drugs, aripiprazole should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. **Potential for Cognitive and Motor Impairment:** In short-term, placebo-controlled trials, somnolence was reported in 11% of patients on ABILIFY compared to 8% of patients on placebo; somnolence led to discontinuation in 0.1% (1/926) of patients on ABILIFY in short-term, placebo-controlled trials. Despite the relatively modest increased incidence of somnolence compared to placebo, ABILIFY, like other antipsychotics, may have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ABILIFY does not affect them adversely. **Body Temperature Regulation:** Disruption of the body's ability to regulate core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing aripiprazole for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. **Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. Aripiprazole and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia (see **PRECAUTIONS: Use in Patients with Concomitant Illness**). **Suicide:** The possibility of a suicide attempt is inherent in psychotic illnesses, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for ABILIFY should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose. **Use in Patients with Concomitant Illness: Safety Experience in Elderly Patients with Psychosis Associated with Alzheimer's Disease:** In a flexible dose (2 to 15 mg/day), 10-week, placebo-controlled study of aripiprazole in elderly patients (mean age: 81.5 years; range: 56 to 95 years) with psychosis associated with Alzheimer's dementia, 4 of 105 patients (3.8%) who received ABILIFY died compared to no deaths among 102 patients who received placebo during or within 30 days after termination of the double-blind portion of the study. Three of the patients (age 92, 91, and 87 years) died following the discontinuation of ABILIFY (aripiprazole) in the double-blind phase of the study (causes of death were

pneumonia, heart failure, and shock). The fourth patient (age 78 years) died following hip surgery while in the double-blind portion of the study. The treatment-emergent adverse events that were reported at an incidence of $\geq 5\%$ and having a greater incidence than placebo in this study were accidental injury, somnolence, and bronchitis. Eight percent of the ABILIFY-treated patients reported somnolence compared to one percent of placebo patients. In a small pilot, open-label, ascending-dose cohort study ($n=30$) in elderly patients with dementia, ABILIFY was associated in a dose-related fashion with somnolence. The safety and efficacy of ABILIFY in the treatment of patients with psychosis associated with dementia have not been established. If the prescriber elects to treat such patients with ABILIFY, vigilance should be exercised, particularly for the emergence of difficulty swallowing or excessive somnolence, which could predispose to accidental injury or aspiration. Clinical experience with ABILIFY in patients with certain concomitant systemic illnesses (see **CLINICAL PHARMACOLOGY: Special Populations: Renal Impairment and Hepatic Impairment**) is limited. ABILIFY has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies.

Information for Patients: Physicians are advised to consult full prescribing information to review issues to be discussed with patients for whom they prescribe ABILIFY.

Drug-Drug Interactions: Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol. Due to its α_1 -adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. **Potential for Other Drugs to Affect ABILIFY:** Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely. Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (e.g., carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. **Ketoconazole:** Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; weaker inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. **Quinidine:** Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112%; but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. **Carbamazepine:** Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in C_{max} and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced. No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see **CLINICAL PHARMACOLOGY: Drug-Drug Interactions**). **Potential for ABILIFY to Affect Other Drugs:** Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. **In vivo** studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates. Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism *in vitro* (see **CLINICAL PHARMACOLOGY: Drug-Drug Interactions**). **Alcohol:** There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. As with most psychotropic medications, patients should be advised to avoid alcohol while taking ABILIFY. **Carcinogenesis, Mutagenesis, Impairment of Fertility:** (Please see Full Prescribing Information).

Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. It is not known whether aripiprazole can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Aripiprazole should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. **Labor and Delivery:** The effect of aripiprazole on labor and delivery in humans is unknown. **Nursing Mothers:** Aripiprazole was excreted in milk of rats during lactation. It is not known whether aripiprazole or its metabolites are excreted in human milk. It is recommended that women receiving aripiprazole should not breast-feed.


Pediatric Use: Safety and effectiveness in pediatric and adolescent patients have not been established. **Geriatric Use:** Of the 5592 patients treated with aripiprazole in premarketing clinical trials, 659 (12%) were ≥ 65 years old and 525 (9%) were ≥ 75 years old. The majority (91%) of the 659 patients were diagnosed with dementia of the Alzheimer's type. Placebo-controlled studies of aripiprazole in schizophrenia did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. There was no effect of age on the pharmacokinetics of a single 15-mg dose of aripiprazole. Aripiprazole clearance was decreased by 20% in elderly subjects (≥ 65 years) compared to younger adult subjects (18 to 64 years), but there was no detectable effect of age in the population pharmacokinetic analysis in schizophrenia patients. Studies of elderly patients with psychosis associated with Alzheimer's disease, have suggested that there may be a different tolerability profile in this population compared to younger patients with schizophrenia (see **PRECAUTIONS: Use in Patients with Concomitant Illness**). The safety and efficacy of ABILIFY in the treatment of patients with psychosis associated with Alzheimer's disease has not been established. If the prescriber elects to treat such patients with ABILIFY, vigilance should be exercised.

ADVERSE REACTIONS

Aripiprazole has been evaluated for safety in 5592 patients who participated in multiple-dose premarketing trials in schizophrenia, bipolar mania, and dementia of the Alzheimer's type, and who had approximately 3639 patient-years of exposure. **Adverse Findings Observed in Short-Term, Placebo-Controlled Trials of Patients with Schizophrenia:** The following findings are based on a pool of five placebo-controlled trials (four 4-week and one 6-week) in which aripiprazole was administered in doses ranging from 2 to 30 mg/day. **Adverse Events Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials:** Overall, there was no difference in the incidence of discontinuation due to adverse events between aripiprazole-treated (7%) and placebo-treated (9%) patients. The types of adverse events that led to discontinuation were similar between the aripiprazole and placebo-treated patients. **Adverse Events Occurring at an Incidence of $\geq 2\%$ Among Aripiprazole-Treated Patients and Greater than Placebo in Short-Term, Placebo-Controlled Trials:** Treatment-emergent adverse events that occurred during acute therapy (up to 6 weeks) at an incidence of 2% or more of patients treated with aripiprazole (doses ≥ 2 mg/day) and for which the incidence was greater than the incidence reported for placebo were, *body as a whole*—headache, asthenia, and fever; *Digestive System*—nausea, vomiting, and constipation; *Nervous System*—anxiety, insomnia, lightheadedness, somnolence, akathisia, and tremor; *Respiratory System*—rhinitis and coughing; *Skin and*

Appendages—rash; *Special Senses*—blurred vision. **Dose-Related Adverse Events:** The only adverse event to have a possible dose response relationship, and then most prominently only with 30 mg, was somnolence (placebo, 7.7%; 15-mg, 8.7%; 20-mg, 7.5%; 30-mg, 15.3%). **Extrapyramidal Symptoms:** In short-term, placebo-controlled trials, the incidence of reported EPS for aripiprazole-treated patients was 6% vs. 6% for placebo. Objectively collected data from those trials on the Simpson Angus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia), and the Assessments of Involuntary Movement Scales (for dyskinesias) also did not show a difference between aripiprazole and placebo, with the exception of the Barnes Akathisia Scale (aripiprazole, 0.08; placebo, -0.05). **Laboratory Test Abnormalities:** A between group comparison for 4- to 6-week placebo-controlled trials revealed no medically important differences between aripiprazole and placebo groups in the proportions of patients experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. **Weight Gain:** In short-term trials, there was a slight difference in mean weight gain between aripiprazole and placebo patients (+0.7 kg vs. -0.05 kg, respectively), and also a difference in the proportion of patients meeting a weight gain criterion of $\geq 7\%$ of body weight (aripiprazole (8%) compared to placebo (3%)). **ECG Changes:** Between group comparisons for pooled placebo-controlled trials revealed no significant differences between aripiprazole and placebo in the proportion of patients experiencing potentially important changes in ECG parameters; within the dose range of 10 to 30 mg/day, aripiprazole tended to slightly shorten the QTc interval. Aripiprazole was associated with a median increase in heart rate of 4 beats per minute compared to a 1 beat per minute increase among placebo patients. **Other Adverse Events Observed During Clinical Trials:** Following is a list of modified COSTART terms that reflect treatment-emergent adverse events reported by patients treated with aripiprazole with multiple doses ≥ 2 mg/day during any phase of a trial within the database of 5592 patients. It is important to emphasize that, although the events reported occurred during treatment with aripiprazole, they were not necessarily caused by it. Frequent events occurred in at least 1/100 patients; infrequent events occurred in 1/100 to 1/1000 patients; rare events in fewer than 1/1000 patients. **Body as a Whole:** *Infectious*—flu syndrome, peripheral edema, chest pain, neck pain, neck rigidity; *Infectious*—pelvic pain, scidic attempt, face edema, malaise, photosensitivity, arm rigidity, jaw pain, chills, bloating, jaw tightness, enlarged abdomen, chest tightness; *Rare*—throat pain, back tightness, head heaviness, moniliasis, throat tightness, leg rigidity, neck tightness, Mendelson's syndrome, heat stroke. **Cardiovascular System:** *Frequent*—hypertension, tachycardia, hypotension, bradycardia; *Infectious*—palpitation, hemorrhage, myocardial infarction, prolonged QT interval, cardiac arrest, atrial fibrillation, heart failure, AV block, myocardial ischemia, phlebitis, deep vein thrombosis, angina pectoris, extrasystoles; *Rare*—vasovagal reaction, cardiomegaly, atrial flutter, thrombophlebitis. **Digestive System:** *Frequent*—anorexia, nausea and vomiting; increased appetite, gastroenteritis, dysphagia, flatulence, gastritis, tooth caries, gingivitis, hemorrhoids, gastroesophageal reflux, gastrointestinal hemorrhage, peridontal abscess, tongue edema, fecal incontinence, colitis, rectal hemorrhage, stomatitis, mouth ulcer, cholelithiasis, fecal impaction, oral moniliasis, cholelithiasis, eructation, intestinal obstruction, peptic ulcer; *Rare*—esophagitis, gum hemorrhage, glossitis, hematemesis, melena, duodenal ulcer, chelitis, hepatitis, hepatomegaly, pancreatitis, intestinal perforation. **Endocrine System:** *Infectious*—hypothyroidism; *Rare*—goiter, hyperthyroidism. **Hemic/Lymphatic System:** *Frequent*—ecchymosis, anemia; *Infectious*—hypochromic anemia, leukopenia, leukocytosis, lymphadenopathy, thrombocytopenia; *Rare*—eosinophilia, thrombocytopenia, macrocytic anemia. **Metabolic and Nutritional Disorders:** *Frequent*—weight loss, creatine phosphokinase increased; *Infectious*—dehydration, edema, hypercholesterolemia, hyperglycemia, hypokalemia, diabetes mellitus, SGPT increased, hyperlipidemia, hypoglycemia, thirst, BUN increased, hypонатremia, SGOT increased, alkaline phosphatase increased, iron deficiency anemia, creatinine increased, bilirubinemia, lactic dehydrogenase increased, obesity; *Rare*—hyperkalemia, gout, hypernatremia, cyanosis, hyperuricemia, hypoglycemic reaction. **Musculoskeletal System:** *Frequent*—muscle cramp; *Infectious*—arthritis, bone pain, myositis, arthritis, arthrosis, muscle weakness, spasm, bursitis; *Rare*—rhabdomyolysis, tendonitis, tenosynovitis, rheumatoid arthritis, myopathy. **Nervous System:** *Frequent*—depression, nervousness, increased salivation, hostility, suicidal thought, manic reaction, abnormal gait, confusion, cogwheel rigidity; *Infectious*—dystonia, twitch, impaired concentration, paresthesia, vasodilation, hyperesthesia, extremity tremor, incontinence, bradycardia, decreased libido, panic attack, apathy, dyskinesia, hypersomnia, vertigo, dysarthria, tardive dyskinesia, ataxia, impaired memory, stupor, increased libido, anemia, cerebrovascular accident, hyperactivity, depersonalization, hypokinesia, restless leg, myoclonus, dysphoria, neuropathy, increased reflexes, slowed thinking, hyperkinesia, hyperesthesia, hypotonia, oculogyric crisis; *Rare*—delirium, euphoria, buccoglossal syndrome, akinesia, blunted affect, decreased consciousness, incoordination, cerebral ischemia, decreased reflexes, obsessive thought, intracranial hemorrhage. **Respiratory System:** *Frequent*—dyspnea, pneumonia; *Infectious*—asthma, epistaxis, hiccup, laryngitis; *Rare*—hemoptysis, aspiration pneumonia, increased sputum, dry nasal passages, pulmonary edema, pulmonary embolism, hypoxia, respiratory failure, apnea. **Skin and Appendages:** *Frequent*—dry skin, pruritus, sweating, skin ulcer; *Infectious*—acne, vesiculobullous rash, eczema, alopecia, psoriasis, seborrhea; *Rare*—maculopapular rash, exfoliative dermatitis, urticaria. **Special Senses:** *Frequent*—conjunctivitis, ear pain; *Infectious*—dry eye, eye pain, linitis, otitis media, cataract, altered taste, diplopia; *Rare*—increased lacrimation, frequent blinking, otitis externa, amblyopia, deafness, diplopia, eye hemorrhage, photophobia. **Urogenital System:** *Frequent*—urinary incontinence; *Infectious*—cystitis, urinary frequency, leukorrhea, urinary retention, hematuria, dysuria, anorexia, abnormal ejaculation, vaginal hemorrhage, vaginal moniliasis, kidney failure, urinary hematuria, menorrhagia, albuminuria, kidney calculus, nocturia, polyuria, urinary urgency; *Rare*—breast pain, cervicitis, female lactation, anorgasm, urinary burning, glycosuria, gynecostoma, urolithiasis, priapism.

OVERDOSAGE


Management of Overdose: No specific information is available on the treatment of overdose with aripiprazole. An electrocardiogram should be obtained in case of overdose and, if QTc interval prolongation is present, cardiac monitoring should be instituted. However, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers. **Charcoal**—In the event of an overdose of ABILIFY, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15 mg oral dose of aripiprazole, decreased the mean AUC and C_{max} of aripiprazole by 50%. **DRUG ABUSE AND DEPENDENCE**
Controlled Substance: ABILIFY (aripiprazole) is not a controlled substance. **Abuse and Dependence:** Aripiprazole has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. In physical dependence studies in monkeys, withdrawal symptoms were observed upon abrupt cessation of dosing. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of ABILIFY misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior). Marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850 USA and Bristol-Myers Squibb Co., Princeton, NJ 08543 USA. Manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan. Distributed by Bristol-Myers Squibb Co., Princeton, NJ 08543 USA.  Bristol-Myers Squibb Company, Princeton, NJ 08543 USA.  Otsuka America Pharmaceutical, Inc., Princeton, NJ 08543 USA.

D6-B001A-11-02 A4115/10-02 Issued: November 2002

©2003 Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan.

A different path to success in your continuing treatment of schizophrenia.

Prescribe now



ABILIFY™

(aripiprazole)

Abilify is indicated for the treatment of schizophrenia.

As with all antipsychotic medications, a rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported. As with all antipsychotic medications, prescribing should be consistent with the need to minimize the risk of tardive dyskinesia (TD). Abilify may be associated with orthostatic hypotension and should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension. Seizures occurred in 0.1% of Abilify-treated patients in short-term, placebo-controlled trials. As with other antipsychotic drugs, Abilify should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Treatment-emergent adverse events reported at an incidence of $\geq 10\%$ and greater than placebo include headache, anxiety, insomnia, nausea, vomiting, lightheadedness, somnolence, akathisia, and constipation.

Please see Brief Summary of Prescribing Information on adjacent page. For more information, visit our web site at www.abilify.com.

Marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850 USA and Bristol-Myers Squibb Co., Princeton, NJ 08543.

Manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan. Distributed by Bristol-Myers Squibb Co., Princeton, NJ 08543. U.S. Patent Nos. 4,734,416 and 5,006,528.

©2003 Otsuka Pharmaceutical Co., Ltd., Rockville, MD.
D6-K0048 A4228/05-03 June 2003

 Bristol-Myers Squibb Company

 Otsuka America Pharmaceutical, Inc.

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

Table of Contents

June 2003
Volume 8 - Number 6

Feature Articles

REVIEW

421 Venlafaxine Treatment of Obsessive-Compulsive Disorder: Case Reports

By Donatella Marazziti, MD

ORIGINAL RESEARCH

428 Topiramate in the Preventive Treatment of Episodic Migraine: A Comorbid Analysis From Pilot, Double-Blind, Placebo-Controlled Trials

By Keith R. Edwards, MD, Doreen L. Potter, RPA-C, Shu-Chen Wu, PhD, Marc Kamin, MD, and Joseph Hulihan, MD

CME Accredited Articles

REVIEW

433 The Comorbidity of Migraine

By Nancy C.P. Low, MD, MS, and Kathleen Ries Merikangas, PhD

REVIEW

446 The Link Between Glutamate and Migraine

By Nabih M. Ramadan, MD

ORIGINAL RESEARCH

450 Restless Legs Syndrome and Drug-Induced Akathisia in Headache Patients

By William B. Young, MD, Elcio J. Piovesan, MD, and Kevin M. Biglan, MD

CNS Spectrums is an *Index Medicus* journal and is available on MEDLINE under the citation *CNS Spectr.*

It is also indexed by DIALOG, EMBASE/Excerpta Medica, OVID, Lexis-Nexis, and SilverPlatter.

CNS Spectrums is the official journal of the International Neuropsychiatric Association with members in 30 countries.

CNS Spectrums®
(ISSN 1092-8529)

is published monthly by
MBL Communications, Inc.
333 Hudson Street, 7th Floor
New York, NY 10013

One year subscription rates:
domestic \$120;
foreign \$185;
in-training \$75.

For subscriptions:
Fax 212-328-0600
or visit our Web site:
www.cnsspectrums.com

Postmaster:
Send address changes to
CNS Spectrums
c/o PPS Medical Marketing Group
264 Passaic Avenue
Fairfield, NJ 07004-2595

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

Table of Contents

June 2003
Volume 8 - Number 6

Departments/Monthly Columns

FROM THE EDITOR'S DESK

406 Migraine and Its Connection to Neurology and Psychiatry

By Jack M. Gorman, MD

CNS DIGEST

415 In the Journal of June 2003

- *Case by Case: Venlafaxine and Obsessive-Compulsive Disorder*
- *What is the Efficacy of the Antiepileptic Topiramate in Migraine?*
- *Disorders in Conjunction With Migraine*
- *Migraine and Glutamate: How are They Related?*
- *Treating Drug-Induced Side Effects in Patients With Headache*

CLINICAL UPDATES IN NEUROLOGY

416 News From the 55th Annual Meeting of the American Academy of Neurology

- *Topiramate Found Effective in Treating Migraines*
- *Researchers Develop Effective Treatment for Restless Legs Syndrome*
- *Deep Brain Stimulation Progressively Improves Generalized Torsion Dystonia*
- *Statin Found to Lower Brain Lesions in Multiple Sclerosis Patients*
- *Botulinum Toxin A Improves the Quality of Life of Cerebral Palsy Patients*

THE NEUROLOGY OF BEHAVIOR

420 Magnetic Resonance Imaging and Hallervorden-Spatz Syndrome

By Michael Trimble, MD, FRCP, FRPsych

CONTINUING MEDICAL EDUCATION

457 The CME quiz on migraines is accredited by Mount Sinai School of Medicine for 3.0 credit hours in Category 1.

For editorial inquiries, please fax us at 212-328-0600 or e-mail us at jrr@mbllcommunications.com.

For advertising inquiries, please fax us at 212-328-0600 or e-mail us at: ek@mbllcommunications.com
kjs@mbllcommunications.com.

For bulk reprint purchases, please contact: Marsha Fogler, Sheridan Reprints, at 1-800-482-1450

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board.

Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums® is a registered trademark of *CNS Spectrums*, LLC, New York, NY.


Permission to reproduce articles in whole or part must be obtained in writing from the publisher.



Audit Bureau of Circulations
MEMBER SINCE 2001

Copyright ©2003 by MBL Communications, Inc. All rights reserved.

Printed in the United States.



Now available



Xanax XR[®]
alprazolam extended-release tablets **IV**